Sarabia-Sainz Andre-I, Ramos-Clamont Gabriela, Winzerling Joy, Vázquez-Moreno Luz
Laboratorio de Bioquímica de Proteínas, Coordinación de Ciencia de los Alimentos, Centro de Investigación en Alimentación y Desarrollo A.C. (CIAD A.C.), Hermosillo, Sonora, Mexico.
Acta Biochim Pol. 2011;58(1):95-100. Epub 2011 Mar 14.
Recently, glyco-therapy is proposed to prevent the interaction of bacterial lectins with host ligands (glycoconjugates). This interaction represents the first step in infection. Neoglycans referred to as PSA-Lac (PSA-Glu (β1-4) Gal) were obtained by conjugation of porcine serum albumin (PSA) with lactose at 80 °C, 100 °C and 120 ºC. Characterization studies of the products showed that PSA could contain 1, 38 or 41 added lactoses, depending on the reaction temperature. These neoglycans were approximately 10 times more glycated than PSA-Lac obtained in previous work. Lactose conjugation occurred only at lysines and PSA-Lac contained terminal galactoses as confirmed by Ricinus communis lectin recognition. Furthermore, Escherichia coli K88+, K88ab, K88ac and K88ad adhesins showed affinity toward all PSA-Lac neoglycans, and the most effective was the PSA-Lac obtained after 100 ºC treatment. In vitro, this neoglycan partially inhibited the adhesion of E. coli K88+ to piglet mucin (its natural ligand). These results provide support for the hypothesis that glycated proteins can be used as an alternative for bioactive compounds for disease prevention.
最近，有人提出采用糖疗法来阻止细菌凝集素与宿主配体（糖缀合物）之间的相互作用。这种相互作用是感染的第一步。通过在80℃、100℃和120℃下将猪血清白蛋白（PSA）与乳糖缀合，得到了被称为PSA-Lac（PSA-Glu(β1-4)Gal）的新糖。对产物的表征研究表明，根据反应温度的不同，PSA可能含有1个、38个或41个添加的乳糖。这些新糖的糖化程度比之前工作中获得的PSA-Lac高约10倍。乳糖缀合仅发生在赖氨酸处，并且蓖麻凝集素识别证实PSA-Lac含有末端半乳糖。此外，大肠杆菌K88 +、K88ab、K88ac和K88ad黏附素对所有PSA-Lac新糖均表现出亲和力，其中最有效的是100℃处理后得到的PSA-Lac。在体外，这种新糖部分抑制了大肠杆菌K88 +与仔猪黏蛋白（其天然配体）的黏附。这些结果为糖化蛋白可作为预防疾病的生物活性化合物的替代物这一假说提供了支持。
